减肥和喘控制:随机对照试验的系统审查
Mahdieh Abbasalizad Farhangi1, George Doumat2, Isis F Baroni2
1Department of Community Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
概括
在患有喘的患者中,减肥显著改善了喘控制和肺功能 (FEV1pp). 由于高质量的研究数量有限,需要进一步的研究.
科学领域:
- 肺部医学 肺部医学
- 代谢健康 代谢健康
- 临床研究 临床研究
背景情况:
- 喘管理通常涉及解决伴随性疾病.
- 肥胖是喘患者常见的并发症.
- 减肥对喘控制的影响需要系统评估.
研究的目的:
- 系统地审查和元分析减肥对喘控制的影响.
- 评估减肥对生活质量 (QOL) 和喘临床结果的影响.
- 评估正在接受减肥干预的喘患者的螺旋测量结果.
主要方法:
- 在PubMed,CINAHL和OVID Medline数据库中进行系统搜索.
- 包括2000年至2023年间发表的12项随机对照试验 (n=1052).
- 使用加权平均差异 (WMD) 和95%置信区间 (CI) 的元分析,并进行子组和元回归分析.
主要成果:
- 减肥显著降低了喘控制问卷 (ACQ) 的得分 (WMD -0.67).
- 在1秒内预测的强迫呼气体积 (FEV1pp) 随着体重减轻而改善 (WMD 13.08).
- 在QOL或预测的强迫生命能力百分比 (FVCpp) 中没有观察到统计学上显著的改善.
结论:
- 减肥与改善喘控制和FEV1pp.相关.
- 在体重变化和FEV1pp.之间发现了剂量反应关系.
- 需要更多高质量的临床试验来证实这些发现并描述好处.
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
231
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
231


